黄连素联合阿托伐他汀对AIS病人血清MIF、MONO％及动脉硬化程度的影响

摘要

Objective To investigate the effects of berberine and atorvastatin on serum macrophage migration inhibitory factor (MIF),monocyte proportion (MONO％) and degree of arteriosclerosis in patients with acute ischemic stroke (AIS).Methods One hundred and twenty patients with AIS were recruited and randomly divided into combined group (n =60) and atorvastatin group (n =60).All patients received basic treatment of AIS.The patients in combined group received berberine and atorvastatin.The patients in atorvastatin group received atorvastatin.The levels of serum MIF,MONO％,(day 1 and day 14) and the nerve function defect grades(day 1,day 14 and day 90) were measured.All patients received the color doppler ultrasound inspection(day 1 and day 90).Results There was positive correlation of serum MIF,MONO％,and National Institutes of Health Stroke Scale (NIHSS) scores (P ＜0.05).The levels of serum MIF,MONO％,NIHSS,scores,and degree of arteriosclerosis were no significant relationship between combined group and atorvastatin group on day 1(P ＞0.05).The levels of serum MIF,MONO％ and NIHSS scores of the two groups on day 14 were significantly lower thotin than those on day 1(P ＜0.05).The levels of serum MIF,MONO％ and NIHSS scores of combined group were significantly lower than thotin atorvastatin group's on day 14(P ＜0.05).The mRS scores of combined group were significantly lower than that in atorvastatin group's on day 90(P ＜0.05),and the degree of arteriosclerosis of combined group was significantly alleviated than that in atorvastatin group on day 90(P ＜0.05).Conclusion Berberine and atorvastatln can significantly down-regulate the levels of serum MIF,MONO％,alleviate the degree of arteriosclerosis,improve neurological impairment in patients with AIS.%目的 探讨黄连素联合阿托伐他汀对急性缺血性脑卒中(AIS)病人血清巨噬细胞移动抑制因子(MIF)和单核细胞比率(MONO％)及动脉硬化程度的影响.方法 选择120例AIS病人,随机分为联合组(n=60)和阿托伐他汀组(n=60),均给予AIS常规治疗,联合组给予黄连素+阿托伐他汀,阿托伐他汀组给予阿托伐他汀.检测所有病人的血清MIF、MONO％水平(入院第1天、第14天)及神经功能评分(入院第1天、第14天、第90天).所有病人给予颈部血管彩超检查(第1天、第90天).结果 两组血清MIF、MONO％水平与同时间点美国国立卫生研究院卒中量表(NIHSS)评分呈正相关(P＜0.05);入院第1天,两组血清MIF、MONO％水平、NIHSS评分及动脉硬化指标比较,差异无统计学意义(P＞0.05);入院第14天较第1夭,两组血清MIF、MONO％水平及NIHSS评分均显著下降(P＜0.05);入院第14天,联合组较阿托伐他汀组血清MIF、MONO％水平及NIHSS评分显著下降(P＜0.05);第90天,联合组较阿托伐他汀组mRS评分显著偏低(P＜0.05),短期预后率明显偏高(P＜0.05),动脉硬化指标显著好转(P＜0.05).结论 黄连素联合阿托伐他汀治疗急性缺血性脑卒中可显著降低血清MIF、MONO％水平,并降低动脉硬化程度,促进神经功能恢复,改善短期预后.